8P STC1, a baseline predictive biomarker for overall survival in metastatic colorectal cancer (mCRC)

Abstract

Methods: Within the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), a retrospective multicenter cohort study was performed with a median follow-up of 5.5-years. Immunohistochemical analysis of tumor protein 53 (p53), estrogen receptor (ER), progesterone receptor (PR) and L1 cell-adhesion molecule (L1CAM) expression were analyzed on pre-operative specimens. Biomarker expression was related to LN status, defined as positive (N1), negative (N0) or unknown (Nx). Correlations and Cox regression analysis were performed.Results: A total of 763 EC patients were included in this study cohort. Lymphadenectomy was performed in 64.6% patients of whom 6.9% had N1. Adjuvant treatment was applied in 46.5% patients. Abnormal p53 (p53-abn) expression was observed in 14.7%, L1CAM expression in 10.4%, loss of ER in 10.0%, and loss of PR in 18.1%. Significant reduced disease specific survival (DSS) and/or recurrence free survival (RFS) was observed within patients with N1 + p53-abn, L1CAM positive expression, or loss of ER/PR. N1 + normal biomarkers show the same prognosis as patients with N0 or Nx + abnormal biomarkers. In the multivariate Cox regression analysis loss of ER/PR and p53-abn were in addition to the ESMO classification 'high-intermediate and high' significantly associated with decreased DSS .81] p¼<0.001). Conclusions:We have shown that abnormal biomarker expression in addition to N1 or N0, is highly relevant in survival analysis and could potentially complement the ESMO risk stratification and therefore optimize adjuvant treatment.Legal entity responsible for the study: The authors.